Marius Breheret1, Dorota Lubgan1, Marlen Haderlein1, Markus Hecht1, Maximilian Traxdorf2, Daniela Schmidt3, Sarina Müller2, Christian Kitzsteiner1, Torsten Kuwert3, Heinrich Iro2, Rainer Fietkau1, Sabine Semrau4. 1. Department of Radiation Oncology, University Hospital, Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Universitätsstrasse 27, 91054, Erlangen, Germany. 2. Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital, Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Waldstrasse 1, 91054, Erlangen, Germany. 3. Department of Nuclear Medicine, University Hospital, Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Ulmenweg 18, 91054, Erlangen, Germany. 4. Department of Radiation Oncology, University Hospital, Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Universitätsstrasse 27, 91054, Erlangen, Germany. sabine.semrau@uk-erlangen.de.
Abstract
INTRODUCTION: The response to induction chemotherapy (IC) predicts local control after conservative treatment of laryngeal, meso- and hypopharyngeal head and neck squamous cell carcinoma (HNSCC) and can thus help to avoid surgery. Single-cycle induction chemotherapy may help to maintain a low local recurrence rate while keeping the overall toxicity manageable. However, long-term data on single-cycle IC response by tumor location is lacking. METHODS: N = 102 patients with functionally inoperable primary HNSCC of the larynx (n = 43), hypopharynx (n = 42) or mesopharynx/tongue (n = 17) received one cycle of docetaxel (75 mg/m2, d1) plus cisplatin (30 mg/m2, d1-3) or carboplatin (AUC 1.5, d1-3) and a response evaluation 3 weeks later. Responders (≥ 30% tumor size reduction and ≥ 20% SUVmax decrease in 18F-FDG PET/CT) were recommended chemoradiotherapy (CRT), and non-responders surgery. RESULTS: The overall response rate was 72.5%. All 74 responders and 10 non-responders received primary CRT, and 18 patients received primary surgery after single-cycle IC. Overall 10-year local recurrence-free survival (LRFS) was 73.7%. Three-year LRFS was 88.2% (mesopharynx/tongue), 88.2% (larynx), and 73.3% (hypopharynx); p = 0.17. 3-year distant metastasis-free survival (DMFS) was 94.1% (mesopharynx/tongue), 88.0% (larynx) and 76.4% (hypopharynx); p > 0.05. This influenced the 3-year cancer-specific survival (CSS) for larynx (91.2%) vs. hypopharynx tumors (60.8%); p = 0.003, but CSS was not different to tumors in the mesopharynx/tongue (81.4%); p > 0.05. CONCLUSIONS: A single-cycle induction chemotherapy for HNSCC enables surgery plus adjuvant therapy as well as chemoradiotherapy. The long-term local and distant disease control was good but varied between tumors in the larynx and mesopharynx/tongue vs. hypopharynx.
INTRODUCTION: The response to induction chemotherapy (IC) predicts local control after conservative treatment of laryngeal, meso- and hypopharyngeal head and neck squamous cell carcinoma (HNSCC) and can thus help to avoid surgery. Single-cycle induction chemotherapy may help to maintain a low local recurrence rate while keeping the overall toxicity manageable. However, long-term data on single-cycle IC response by tumor location is lacking. METHODS: N = 102 patients with functionally inoperable primary HNSCC of the larynx (n = 43), hypopharynx (n = 42) or mesopharynx/tongue (n = 17) received one cycle of docetaxel (75 mg/m2, d1) plus cisplatin (30 mg/m2, d1-3) or carboplatin (AUC 1.5, d1-3) and a response evaluation 3 weeks later. Responders (≥ 30% tumor size reduction and ≥ 20% SUVmax decrease in 18F-FDG PET/CT) were recommended chemoradiotherapy (CRT), and non-responders surgery. RESULTS: The overall response rate was 72.5%. All 74 responders and 10 non-responders received primary CRT, and 18 patients received primary surgery after single-cycle IC. Overall 10-year local recurrence-free survival (LRFS) was 73.7%. Three-year LRFS was 88.2% (mesopharynx/tongue), 88.2% (larynx), and 73.3% (hypopharynx); p = 0.17. 3-year distant metastasis-free survival (DMFS) was 94.1% (mesopharynx/tongue), 88.0% (larynx) and 76.4% (hypopharynx); p > 0.05. This influenced the 3-year cancer-specific survival (CSS) for larynx (91.2%) vs. hypopharynx tumors (60.8%); p = 0.003, but CSS was not different to tumors in the mesopharynx/tongue (81.4%); p > 0.05. CONCLUSIONS: A single-cycle induction chemotherapy for HNSCC enables surgery plus adjuvant therapy as well as chemoradiotherapy. The long-term local and distant disease control was good but varied between tumors in the larynx and mesopharynx/tongue vs. hypopharynx.
Entities:
Keywords:
Head and neck squamous cell carcinoma (HNSCC); Induction chemotherapy; Resection; Single-cycle
Authors: A Dietz; G Wichmann; T Kuhnt; L Pfreundner; R Hagen; M Scheich; O Kölbl; M G Hautmann; J Strutz; F Schreiber; U Bockmühl; V Schilling; P Feyer; M de Wit; G Maschmeyer; M Jungehülsing; U Schroeder; B Wollenberg; C Sittel; M Münter; T Lenarz; J P Klussmann; O Guntinas-Lichius; C Rudack; H T Eich; T Foerg; S Preyer; M Westhofen; H J Welkoborsky; D Esser; D Thurnher; S Remmert; H Sudhoff; M Görner; J Bünzel; V Budach; S Held; M Knödler; F Lordick; S Wiegand; K Vogel; A Boehm; M Flentje; U Keilholz Journal: Ann Oncol Date: 2018-10-01 Impact factor: 32.976
Authors: Robert Haddad; Anne O'Neill; Guilherme Rabinowits; Roy Tishler; Fadlo Khuri; Douglas Adkins; Joseph Clark; Nicholas Sarlis; Jochen Lorch; Jonathan J Beitler; Sewanti Limaye; Sarah Riley; Marshall Posner Journal: Lancet Oncol Date: 2013-02-13 Impact factor: 41.316
Authors: Susan Urba; Gregory Wolf; Avraham Eisbruch; Francis Worden; Julia Lee; Carol Bradford; Theodoros Teknos; Douglas Chepeha; Mark Prince; Norman Hogikyan; Jeremy Taylor Journal: J Clin Oncol Date: 2005-12-27 Impact factor: 44.544
Authors: J-L Lefebvre; G Andry; D Chevalier; B Luboinski; L Collette; L Traissac; D de Raucourt; J A Langendijk Journal: Ann Oncol Date: 2012-04-06 Impact factor: 32.976
Authors: Jan B Vermorken; Eva Remenar; Carla van Herpen; Thierry Gorlia; Ricard Mesia; Marian Degardin; John S Stewart; Svetislav Jelic; Jan Betka; Joachim H Preiss; Danielle van den Weyngaert; Ahmad Awada; Didier Cupissol; Heinz R Kienzer; Augustin Rey; Isabelle Desaunois; Jacques Bernier; Jean-Louis Lefebvre Journal: N Engl J Med Date: 2007-10-25 Impact factor: 91.245
Authors: Yoann Pointreau; Pascal Garaud; Sophie Chapet; Christian Sire; Claude Tuchais; Jacques Tortochaux; Sandrine Faivre; Stephane Guerrif; Marc Alfonsi; Gilles Calais Journal: J Natl Cancer Inst Date: 2009-03-24 Impact factor: 13.506
Authors: Arlene A Forastiere; Qiang Zhang; Randal S Weber; Moshe H Maor; Helmuth Goepfert; Thomas F Pajak; William Morrison; Bonnie Glisson; Andy Trotti; John A Ridge; Wade Thorstad; Henry Wagner; John F Ensley; Jay S Cooper Journal: J Clin Oncol Date: 2012-11-26 Impact factor: 44.544
Authors: Renata Fockink Dos Anjos; Dalton Alexandre Dos Anjos; Danielle Leal Vieira; André Ferreira Leite; Paulo Tadeu de Souza Figueiredo; Nilce Santos de Melo Journal: Medicine (Baltimore) Date: 2016-08 Impact factor: 1.889
Authors: M Hecht; S Semrau; M Beck; J Hartwich; M Eckstein; D Schmidt; A O Gostian; S Müller; S Rutzner; U S Gaipl; J von der Grün; T Illmer; M G Hautmann; G Klautke; J Döscher; T Brunner; B Tamaskovics; A Hartmann; H Iro; T Kuwert; R Fietkau Journal: Ann Nucl Med Date: 2022-05-10 Impact factor: 2.258